Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab +/- gp100 Vaccine in Stage IV Melanoma
NCT00357461Phase 2Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- May 2006
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ipilimumab in melanoma, sponsored by Bristol Myers Squibb. Planned start May 2006; status: withdrawn.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00357461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00357461.